Domagala J M, Hagen S E, Hutt M P, Sanchez J P, Sesnie J, Trehan A K
Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105.
Drugs Exp Clin Res. 1988;14(7):453-60.
A series of 5-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3- quinolinecarboxylic acids with piperazinyl or pyrrolidinyl side-chains appended at C7 were prepared to test the effect of the 5-amino group on the biological and physicochemical properties of these quinolones. The target compounds were synthesized from 2-nitro-3,4,5,6-tetrafluorobenzoic acid and were tested against a variety of Gram-negative and Gram-positive bacteria and the bacterial enzyme DNA gyrase, using standard microtitration techniques. The results are compared to reference quinolones such as ciprofloxacin. The 5-amino derivatives were significantly more potent (2-16 times) than their non-amino analogues. Alkylation or acylation of the 5-amino group reduced potency dramatically. The 5-amino group was neither basic nor nucleophilic. 5-Amino-7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl- 6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid (PD 124,816) was selected as the best compound in this study.
制备了一系列在C7位带有哌嗪基或吡咯烷基侧链的5-氨基-1-环丙基-6,8-二氟-1,4-二氢-4-氧代-3-喹啉羧酸,以测试5-氨基对这些喹诺酮类药物生物学和物理化学性质的影响。目标化合物由2-硝基-3,4,5,6-四氟苯甲酸合成,并使用标准微量滴定技术针对多种革兰氏阴性菌和革兰氏阳性菌以及细菌酶DNA促旋酶进行了测试。将结果与环丙沙星等参考喹诺酮类药物进行了比较。5-氨基衍生物比其无氨基类似物的效力显著更高(2至16倍)。5-氨基的烷基化或酰化显著降低了效力。5-氨基既不具有碱性也不具有亲核性。5-氨基-7-(3-氨基-1-吡咯烷基)-1-环丙基-6,8-二氟-1,4-二氢-4-氧代-3-喹啉羧酸(PD 124,816)被选为该研究中的最佳化合物。